ROS1 and melanoma: Recent advances have expanded the role of oncogenic driver genes from targeted therapy to immunotherapy, including STK11, EGFR and KRAS (14–16); however, for our knowledge, there were few studies on variations other than rearrangement concerning ROS1, and what role the ROS1 mutation would act in ICI treatment of melanoma has not yet been elucidated to date.